Cancer Immunology and Immunotherapy Clinical Trials in CCR
Physician-scientists at the Center for Cancer Research are actively testing new immunotherapeutics in clinical trials aimed at improving outcomes for patients with cancer, HIV, or immunodeficiency disorders. Patients are seen at the NIH Clinical Center, the Nation’s largest hospital dedicated entirely to clinical research.
These are generally phase 1 or phase 2 trials, and have included several first-in-human clinical studies. Examples of some of our ongoing trials are identifying new antigen receptor targets for CAR T cells, as well as combining immunotherapy with more standard treatment approaches such as chemotherapy, radiotherapy or cytokines.
Learn more about immunotherapy treatments.
Current Open Trials
If you would like more details on a trial, contact the referral nurse listed.
-
Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Open - Not yet RecruitingNCI Protocol ID NCI-21-C-0014Investigator Christopher J. Melani, M.D. -
A Phase I Study of Adjuvant PRGN-2012 in Adult Patients with Recurrent Respiratory Papillomatosis
Open - Not yet RecruitingNCI Protocol ID NCI-21-C-0013Investigator Scott M. Norberg, D.O. -
Phase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in patients with advanced cancer
Open - Not yet RecruitingNCI Protocol ID NCI-21-C-0007Investigator Houssein Abdul Sater, M.D. -
A Phase I/II Study of Bintrafusp alfa (M7824) and M9241 in Combination with Docetaxel in Adults with Metastatic Castration Sensitive and Castration Resistant Prostate Cancer
Open - RecruitingNCI Protocol ID NCI-21-C-0001Investigator Ravi A. Madan, M.D. -
Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination with BinTrafusp Alfa (M7824 or TGF-ß “Trap”/PD-L1) with CV301 TRICOM in Advanced Solid Tumors (STAT).
Open - RecruitingNCI Protocol ID NCI-20-C-0155Investigator James L. Gulley, M.D., Ph.D. -
A Phase II Study of Bintrafusp alfa (M7824) in Checkpoint Inhibitor Naïve and Refractory Subjects with Urothelial Carcinoma
Open - RecruitingNCI Protocol ID NCI-20-C-0142Investigator Andrea B. Apolo, M.D. -
Phase II Trial of Combination Immunotherapy in Subjects with Advanced Small Bowel and Colorectal Cancers
Open - RecruitingNCI Protocol ID NCI-20-C-0138Investigator Julius Strauss, M.D. -
Phase I/II Trial of HPV Vaccine PRGN-2009 Alone or in Combination with Anti-PD-L1/TGF-ß trap (M7824) in Subjects with HPV Positive Cancers
Open - RecruitingNCI Protocol ID NCI-20-C-0104Investigator Charalampos Floudas, MD, DMSc, MSShare this trial: Referral ContactsContact Name Phone Number NCI Medical Oncology Referral Office (240)760-6050 -
A phase 1/2, open label, dose-escalation, safety and tolerability study of NC410 in subjects with advanced or metastatic solid tumors
Open - RecruitingNCI Protocol ID NCI-20-C-0098Investigator Marijo Bilusic, M.D., Ph.D. -
A Phase I/II Study of the Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination with Stereotactic Body Radiation Therapy (SBRT) in Adults with Advanced Pancreas Cancer.
Open - Not yet RecruitingNCI Protocol ID NCI-20-C-0074Investigator Udo Rudloff, M.D., Ph.D.
- 1 of 5
- next ›